Konrády András, Bencsik Zsuzsa, Locsey Zoltán, Bénik Tamás
Jávorszky Ödön Kórház Vác Argenti Döme tér 1-3. 2600.
Orv Hetil. 2011 Oct 23;152(43):1731-8. doi: 10.1556/OH.2011.29227.
Incidence of differentiated thyroid cancer has increased in the last two decades. This type of cancer is now being diagnosed at an earlier stage. Treatment strategy has been modified.
The goals of this study were to analyze the outcome of differentiated thyroid cancer after initial treatment (surgery and radioiodine ablation) in patients evaluated and followed up in a single centre between l999 and 2009, to compare these results with others as well as to monitor the adoption of international recommendation. 107 patients having T1-T2 differentiated thyroid cancer were studied. Mean follow-up time was 63 months.
After surgery patients were prepared using thyroid hormone withdrawal or recombinant human thyrotropin, then 1.1-3.7 GBq 131-iodine was administered. First year evaluation consisted of ultrasound as well as serum thyrotropin and thyroglobulin (plus thyroglobulin antibody) determinations. Ablation success rate was 83% and the five year survival was 100%. There was not any cancer specific death.
In the future somewhat more radical surgery and less remnant ablation is needed with unified follow-up protocol.
在过去二十年中，分化型甲状腺癌的发病率有所上升。现在这种癌症在更早的阶段被诊断出来。治疗策略已经改变。
本研究的目的是分析1999年至2009年在单一中心接受评估和随访的患者，在初始治疗（手术和放射性碘消融）后分化型甲状腺癌的治疗结果，将这些结果与其他结果进行比较，并监测国际建议的采用情况。研究了107例T1 - T2分化型甲状腺癌患者。平均随访时间为63个月。
手术后，患者采用甲状腺激素撤减或重组人促甲状腺素进行准备，然后给予1.1 - 3.7GBq的131碘。第一年的评估包括超声以及血清促甲状腺素和甲状腺球蛋白（加甲状腺球蛋白抗体）测定。消融成功率为83%，五年生存率为100%。没有任何癌症特异性死亡。
未来需要更激进的手术和更少的残留消融，并采用统一的随访方案。
